Triglav Investments D.O.O. Increases Stock Position in Cencora, Inc. $COR

Triglav Investments D.O.O. lifted its holdings in shares of Cencora, Inc. (NYSE:COR) by 140.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,000 shares of the company’s stock after acquiring an additional 19,300 shares during the period. Triglav Investments D.O.O.’s holdings in Cencora were worth $11,146,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of COR. Oakworth Capital Inc. purchased a new position in shares of Cencora during the fourth quarter worth approximately $26,000. Elyxium Wealth LLC purchased a new position in shares of Cencora during the fourth quarter worth approximately $27,000. Archer Investment Corp grew its position in shares of Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after acquiring an additional 47 shares during the last quarter. IAG Wealth Partners LLC purchased a new position in shares of Cencora during the third quarter worth approximately $30,000. Finally, Cloud Capital Management LLC purchased a new position in shares of Cencora during the third quarter worth approximately $31,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Price Performance

Shares of NYSE COR opened at $269.21 on Friday. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The stock has a fifty day moving average price of $298.56 and a 200 day moving average price of $333.91. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54. The company has a market cap of $52.38 billion, a PE ratio of 20.65, a P/E/G ratio of 1.23 and a beta of 0.64.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. During the same period in the prior year, the business earned $4.42 earnings per share. Cencora’s revenue for the quarter was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts forecast that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora announced that its board has approved a share repurchase plan on Thursday, May 21st that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to buy up to 3.9% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. Cencora’s dividend payout ratio (DPR) is 18.40%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Weiss Ratings lowered shares of Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 22nd. JPMorgan Chase & Co. increased their price target on Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Barclays increased their price target on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Evercore set a $360.00 price target on Cencora in a report on Wednesday, April 8th. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Twelve analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $380.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.